Andrew C. Kruegel

Pharmacology, Toxicology and PharmaceuticsChemistryBiochemistry, Genetics and Molecular BiologyNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Kratom use in the United States: a diverse and complex profile”.

Kratom use in the United States: a diverse and complex profile

Addiction(2020)10.1111/add.15173

N/A

0DataRank · unranked

24 citations

Jane K. Babin, Jack E. Henningfield, Albert Garcia‐Romeu, Andrew C. Kruegel, Walter C. Prozialeck +4 more

Site selective C–H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy

Nature Communications(2021)10.1038/s41467-021-23736-2

N/A

0DataRank · unranked

42 citations

Juraj Galeta, Václav Havel, Melissa Nelson, Abdelfattah Faouzi, Benjamin Bechand +9 more

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.07.22.453441

N/A

0DataRank · unranked

3 citations

Andrew C. Kruegel, Benjamin Bechand, Scot McIntosh, Leia S. Stallings, Alana Hodges +15 more

Structural pharmacology and therapeutic potential of 5-methoxytryptamines

Nature(2024)10.1038/s41586-024-07403-2

N/A

0DataRank · unranked

74 citations

David Lankri, Michael J. Cunningham, Inis C. Serrano, Lyonna F. Parise, Andrew C. Kruegel +8 more

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models

Nature Communications(2024)10.1038/s41467-024-51856-y

N/A

0DataRank · unranked

18 citations

Andrew C. Kruegel, Benjamin Bechand, Scot McIntosh, Leia S. Stallings, Alana Hodges +16 more